trending Market Intelligence /marketintelligence/en/news-insights/trending/wxunEePfurSy4v3EUEOsSQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Rafael Pharmaceuticals' cancer drug receives orphan drug designation in EU

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Rafael Pharmaceuticals' cancer drug receives orphan drug designation in EU

Rafael Pharmaceuticals Inc. said its drug CPI-613 received the orphan drug designation in the EU to treat pancreatic cancer that has spread.

The tag, granted by the European Medicines Agency, is meant to incentivize the development of medicines for conditions that affect less than five in 10,000 people in the region. With the designation in hand, the medicine, which is also known as devimistat, will be eligible for fee reductions, market exclusivity and other benefits once approved.

CPI-613 is being studied across multiple trials in patients with pancreatic cancer, which is hard to diagnose at an early stage and leads to death within five years from the time it has been discovered.

The Newark, N.J.-based company's medicine is also designated as an orphan drug in the U.S. for multiple cancer types, including those of the pancreas.